摘要
目的探讨转化生长因子β受体Ⅱ(TβRⅡ)在肾透明细胞癌(RCCC)中的甲基化状态及其临床意义。方法应用甲基化特异性PCR(MSP)技术检测43例肾透明细胞癌组织,43例正常组织中TβRⅡ基因的甲基化状况;应用免疫组织化学P-V法检测40例肾透明细胞癌组织,28例正常组织中TβRⅡ基因的蛋白表达情况。结果 RCCC组织中TβRⅡ基因的甲基化率为58.1%(25/43),显著高于正常组织34.9%(15/43),差异有统计学意义(P<0.05);肾透明细胞癌中TβRⅡ基因的甲基化率与患者年龄、性别、肿瘤的大小和肿瘤分化程度无显著相关性(P>0.05)。TβRⅡ在RCCC组织中的免疫组化结果显示,基因蛋白表达在RCCC组显著低于正常组(P<0.05),且其蛋白表达与肿瘤的大小和肿瘤分化程度相关(P<0.05)。结论 TβRⅡ基因启动子甲基化可能与RCCC的发生有关。
Objective： The study is to examine TβR Ⅱ gene methylation status and to research its clinical significance in renal clear cell carcinoma （RCCX;）. Methods Methylation-specific PCR （MSP） is applied to detect 43 cases of renal clear cell carcinoma and 43 cases of adjacent normal tissues Ⅱ gene methylation status;in addition, PV immunohistochemistry （IHC） is applied to detect 40 cases of renal clear cell carcinoma and 28 cases of adjacent normal tissues TβR Ⅱ gene protein expression. Results TβR Ⅱ gene in RCCC group and adjacent normal group in the methylation rates were respectively 58.1% （25/43） and 34.9% （15/43）. The difference was statistically significant, that is, the rate of RCCC group was significantly higher than that of methylation adja cent normal group （P〈0.05）; Methylation frequency of TβRⅡ gene in renal clear cell carcinoma has nothing to do with the patient＇s age, sex tumor size and tumor different iation（P 〉 0.05）. TβR Ⅱ in RCCCC tissues by immunohistochemistry showed that gene expression in the RCCC was signifi- cantly lower than that in adjaeent normal group （P〈0.05）, and its protein expression was correlated with tumor size and tumor differentiation （P 〈 0.05 ）. Conclusion The aberrant promoter methylation of TβRⅡ gene was related to tumorigenesis of renal clear cell carcinoma.
出处
《实用临床医药杂志》
CAS
2010年第11期11-14,共4页
Journal of Clinical Medicine in Practice
基金
河北省普通高校强势特色学科基金资助项目
